Hirose Wataru, Kato Yoshihiro, Natsutani Itaru, Takata Makoto, Kitaichi Maiko, Imai Satoki, Hayashi Shun, Arai Yukiyo, Hoshino Kohei, Yoshida Kohzo
Drug Research Division, Sumitomo Dainippon Pharma, 3-1-98 Kasugade-naka, Konohana-ku, Osaka 554-0022, Japan.
Drug Research Division, Sumitomo Dainippon Pharma, 3-1-98 Kasugade-naka, Konohana-ku, Osaka 554-0022, Japan.
Bioorg Med Chem Lett. 2017 Sep 15;27(18):4331-4335. doi: 10.1016/j.bmcl.2017.08.030. Epub 2017 Aug 16.
We describe here the design, synthesis and characterization of a series of 4,5,6,7-tetrahydrooxazolo[4,5-c]pyridines as metabotropic glutamate receptor (mGluR) 5 negative allosteric modulators (NAMs). Optimization of the substituents led to the identification of several compounds with good pharmacokinetic profiles, including long half life and high oral bioavailability, in both rats and monkeys. The receptor occupancy test in the rat cortex revealed favorable brain penetration of these compounds. The reprsentative compound 13 produced oral antidepressant-like effect in the rat forced swimming test (MED: 0.3mg/kg, q.d.).
我们在此描述了一系列4,5,6,7-四氢恶唑并[4,5-c]吡啶作为代谢型谷氨酸受体(mGluR)5负变构调节剂(NAMs)的设计、合成及表征。对取代基的优化使得在大鼠和猴子中鉴定出了几种具有良好药代动力学特征的化合物,包括长半衰期和高口服生物利用度。在大鼠皮层进行的受体占有率测试表明这些化合物具有良好的脑渗透性。代表性化合物13在大鼠强迫游泳试验中产生了口服抗抑郁样效应(最小有效剂量:0.3mg/kg,每日一次)。